Scientists have developed a hydrogel “rest stop” that shields cancer-fighting T cells, delaying their exhaustion and boosting ...

RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers tracked the in situ CAR-T cells to assess their effectiveness and safety.

Autoimmune diseases, such as multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA), affect ...

Lymphoid-derived conventional dendritic cells (L-cDCs) may play a unique function associated with immune suppression and ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

Combining duvelisib and romidepsin may provide a path to stem cell transplant for patients with relapsed or refractory peripheral and cutaneous T-cell lymphomas.  Researchers from Somerville, ...

Current approved CAR T-cell therapy treatments rely on an ex vivo route, in which a patient’s T cells are removed, genetically engineered to target antigens, and put back into the patient. From ...

Dr. Andre Henri Goy shared how CAR T-cell therapy led a retired pilot with lymphoma into remission, showing the impact of personalized treatment decisions.

A Vertex Pharmaceuticals cell therapy for type 1 diabetes is enabling patients to produce insulin, eliminating the need for additional insulin therapy in the vast majority of participants in a key ...